Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + rituximab + ifosfamide + carboplatin + etoposide
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Epcoritamab + rituximab + ifosfamide + carboplatin + etoposide is an investigational chemoimmunotherapy combination regimen. It adds epcoritamab (brand name Epkinly), a subcutaneously administered T-cell-engaging bispecific antibody, to the standard R-ICE salvage chemotherapy backbone (consisting of the anti-CD20 monoclonal antibody rituximab, the alkylating agent ifosfamide, the platinum-based DNA-damaging agent carboplatin, and the topoisomerase inhibitor etoposide). Genmab and AbbVie are developing this combination in the Phase 1b/2 EPCORE NHL-2 trial (specifically arm 10) for adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who are eligible for autologous stem cell transplantation (ASCT). In clinical evaluations, the regimen has demonstrated high overall and complete response rates, serving as an effective bridge to potentially curative ASCT or CAR T-cell therapy.
- Other names
- epcoritamab + R-ICEepcoritamab + R-ICE regimenepcoritamab plus R-ICEepcoritamab plus R-ICE regimenepcoritamab plus rituximab, ifosfamide, carboplatin, and etoposideepcoritamab plus rituximab, ifosfamide, carboplatin, and etoposide phosphate
02
Targets
CD20 (B-lymphocyte antigen CD20)DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on epcoritamab + rituximab + ifosfamide + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + rituximab + ifosfamide + carboplatin + etoposide.